Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amphastar Pharmaceuticals, Inc.

http://www.amphastar.com

Latest From Amphastar Pharmaceuticals, Inc.

News We're Watching: Accenture Expects 'More Human' Tech, Cardiac Genetic Tests In Walmart; And More

Medtech Insight's News We're Watching highlights a few noteworthy industry developments you might have missed: Accenture's new Vision Report addresses the future of "more human" tech in health care; Efemoral secures FDA's breakthrough status for its bioresorbable peripheral stent; Impulse Dynamics secures $135m to support its cardiac contractility modulation; PrecisionLife and Metrodora announced a partnership to address chronic diseases including long COVID; Cardio Diagnostics launches its cardiac epigenetic/genetic tests in a Walmart near Chicago.

News We're Watching Artificial Intelligence

Watch Out GSK! China’s Homegrown Shingles Vaccine Set To Soar

Although the domestic developer did not provide sales figures for 2023, a new homegrown shingles vaccine in China is poised to eat into the market share of GSK’s Shingrix in the country.

China Vaccines

Apotex And Ambio Shatter Hopes Of Teriparatide Exclusivity For Teva

Partners Apotex and Ambio have announced approval of a second US teriparatide generic from the FDA, adding another Forteo rival to the market and removing hopes that Teva’s recently approved first generic could benefit from 180 days of market exclusivity. Further competition is also in the works with Amphastar awaiting FDA action on a further teriparatide ANDA.

Approvals Generic Drugs

Supplier Shortages To Benefit Amphastar For Many Quarters To Come

Amphastar management has assured stakeholders that it will continue to benefit from competitor shortages for the foreseeable future, with chief financial officer Bill Peters noting that the firm has been plugging gaps in the market throughout his near-decade at the company.

Strategy Sales & Earnings
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • OTC, Consumer
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Nasal
      • Pulmonary
  • Other Names / Subsidiaries
    • Amphastar France Pharmaceuticals (AFP)
    • Armstrong Pharmaceuticals, Inc.
    • International Medication Systems (IMS)
    • Nanjing Puyan Pharmaceutical Technology (ANP)
UsernamePublicRestriction

Register